UK medicines export and Windsor Framework labelling requirements

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding significant updates to medicinal packaging requirements effective January 1, 2025. Following the implementation of the Windsor Framework, this regulatory framework requires all medicines intended for the UK market to feature a "UK Only" label on their outer packaging. While this is a general guidance document rather than a report on specific company violations or inspection dates, it establishes mandatory standards for all pharmaceutical manufacturers operating in the region. A primary change includes the removal of European Union Falsified Medicines Directive (FMD) safety features, such as specific 2D barcodes and unique identifiers, for products sold within the UK. The guidance clarifies that these "UK Only" labeled products can still be exported to international territories, provided they meet the specific import requirements of the destination country. Required actions for companies include updating all product artwork to incorporate the new labeling and ensuring supply chain compliance before the transition deadline. International regulators are encouraged to recognize this label as a mark of UK regulatory compliance that does not inherently restrict global distribution.